Aeglea BioTherapeutics Receives $12,000,000 New Financing

  • Feed Type
  • Date
    1/13/2014
  • Company Name
    Aeglea BioTherapeutics
  • Mailing Address
    815-A Brazos St. Austin, TX 78701
  • Company Description
    Aeglea BioTherapeutics is a Texas based start up developing two drugs invented at UT Austin, novel engineered human enzymes that degrade the amino acids L-methionine (L-Met), or L- arginine (LArg) in the circulation. These drugs target the dependence of different tumors on L- Met or L-Arg for survival.
  • Website
    Undisclosed
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $12,000,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    Proceeds purposes were not disclosed.
  • M&A Terms
  • Venture Investor
    Undisclosed

By posting a comment, you agree to our terms and conditions.